Article references (15 references )


  1. Chamie K, Litwin MS, Bassett JC, Daskivich TJ, Lai J, Hanley JM et al. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer. 2013 Sep 01; 119(17):3219-27. PubMed | Google Scholar

  2. Chamie K, Ballon-Landa E, Daskivich TJ, Bassett JC, Lai J, Hanley JM et al. Treatment and survival in patients with recurrent high-risk non-muscle-invasive bladder cancer. Urologic oncology. 2015 Jan; 33(1):20e9-17. PubMed | Google Scholar

  3. Ryk C, Koskela LR, Thiel T, Wiklund NP, Steineck G, Schumacher MC et al. Outcome after BCG treatment for urinary bladder cancer may be influenced by polymorphisms in the NOS2 and NOS3 genes. Redox biology. 2015 Dec; 6:272-7. PubMed | Google Scholar

  4. Zhao H, Liang D, Grossman HB, Wu X. Glutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancer. Urology. 2005 Oct; 66(4):769-74. PubMed | Google Scholar

  5. Decobert M, Larue H, Bergeron A, Harel F, Pfister C, Rousseau F et al. Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. The Journal of urology. 2006 Apr; 175(4):1506-11. PubMed | Google Scholar

  6. Ichimura Y, Habuchi T, Tsuchiya N, Wang L, Oyama C, Sato K et al. Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant. The Journal of urology. 2004 Aug; 172(2):728-32. PubMed | Google Scholar

  7. Moscow JA, Schmidt L, Ingram DT, Gnarra J, Johnson B, Cowan KH. Loss of heterozygosity of the human cytosolic glutathione peroxidase I gene in lung cancer. Carcinogenesis. 1994 Dec; 15(12):2769-73. PubMed | Google Scholar

  8. Ratnasinghe D, Tangrea JA, Andersen MR, Barrett MJ, Virtamo J, Taylor PR et al. Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk. Cancer research. 2000 Nov 15; 60(22):6381-3. PubMed | Google Scholar

  9. Chiong E, Kesavan A, Mahendran R, Chan YH, Sng JH, Lim YK et al. NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guerin therapy for bladder cancer. European urology. 2011 Mar; 59(3):430-7. PubMed | Google Scholar

  10. Lenormand C, Couteau J, Nouhaud FX, Maillet G, Bou J, Gobet F et al. Predictive Value of NRAMP1 and HGPX1 Gene Polymorphism for Maintenance BCG Response in Non-muscle-invasive Bladder Cancer. Anticancer research. 2016 Apr; 36(4):1737-43. PubMed | Google Scholar

  11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003 Sep 06; 327(7414):557-60. PubMed | Google Scholar

  12. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994 Dec; 50(4):1088-101. PubMed | Google Scholar

  13. Chen Y, Zhu G, Wu K, Gao Y, Zeng J, Shi Q et al. FGF2-mediated reciprocal tumor cell-endothelial cell interplay contributes to the growth of chemoresistant cells: a potential mechanism for superficial bladder cancer recurrence. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016 Apr; 37(4):4313-21. PubMed | Google Scholar

  14. Pignot G, le Goux C, Bieche I. Recent advances in bladder urothelial carcinogenesis. Bulletin du cancer. 2015 Dec;102(12):1020-35. PubMed | Google Scholar

  15. Zhuo C, Li X, Zhuang H, Tian S, Cui H, Jiang R et al. Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis. Oncotarget. 2016 Dec 13; 7(50):82567-79. PubMed | Google Scholar